{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"9.2","value":"5.3"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"1.7","value":"1.6"},{"groupId":"OG002","lowerLimit":"1.2","upperLimit":"2.0","value":"1.7"},{"groupId":"OG003","lowerLimit":"1.7","upperLimit":"1.9","value":"1.9"},{"groupId":"OG004","lowerLimit":"1.2","upperLimit":"5.1","value":"1.8"},{"groupId":"OG005","lowerLimit":"0.8","upperLimit":"3.2","value":"2.1"},{"groupId":"OG006","lowerLimit":"0.8","upperLimit":"1.6","value":"0.9"},{"groupId":"OG007","lowerLimit":"0.7","upperLimit":"4.0","value":"1.4"},{"groupId":"OG008","lowerLimit":"1.2","upperLimit":"3.7","value":"1.5"},{"groupId":"OG009","lowerLimit":"0.8","upperLimit":"1.7","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"}],"units":"Participants"}],"description":"Median time for progression free survival was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 45 mg LTT462 QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 twice daily (BID) as oral capsules","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"paramType":"MEDIAN","populationDescription":"The full analysis set included all participants who had received at least one dose of LTT462.","reportingStatus":"POSTED","timeFrame":"Every 2 cycles after starting LTT462 treatment until end of treatment (Up to 2.8 years)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}